aTyr Pharma, Inc. (ATYR) — Cash Flow-to-Debt Ratio
aTyr Pharma, Inc. (ATYR) has a Cash Flow-to-Debt Ratio of -0.45x as of December 2025, meaning its operating cash flow of $-12.20 Million could theoretically repay 0% of its total liabilities ($26.88 Million) in one year. Check ATYR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
aTyr Pharma, Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for aTyr Pharma, Inc. across 14 annual periods. Also explore aTyr Pharma, Inc. total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for aTyr Pharma, Inc. (2012–2025)
Year-by-year debt coverage analysis for aTyr Pharma, Inc.. For market capitalisation and broader financial context, see ATYR market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.31x | $-61.99 Million | $26.88 Million | ▲ +9.9% |
| 2024 | -2.56x | $-69.12 Million | $27.00 Million | ▼ -132.6% |
| 2023 | -1.10x | $-33.22 Million | $30.18 Million | ▲ +35.6% |
| 2022 | -1.71x | $-41.89 Million | $24.50 Million | ▲ +66.9% |
| 2021 | -5.16x | $-33.08 Million | $6.41 Million | ▼ -144.2% |
| 2020 | -2.11x | $-15.30 Million | $7.24 Million | ▼ -60.1% |
| 2019 | -1.32x | $-20.01 Million | $15.16 Million | ▲ +18.9% |
| 2018 | -1.63x | $-31.06 Million | $19.10 Million | ▲ +3.6% |
| 2017 | -1.69x | $-42.36 Million | $25.11 Million | ▲ +43.4% |
| 2016 | -2.98x | $-52.86 Million | $17.72 Million | ▼ -18.5% |
| 2015 | -2.52x | $-36.80 Million | $14.62 Million | ▼ -1130.8% |
| 2014 | -0.20x | $-22.82 Million | $111.65 Million | ▼ -25.0% |
| 2013 | -0.16x | $-17.31 Million | $105.87 Million | ▲ +87.5% |
| 2012 | -1.30x | $-11.38 Million | $8.73 Million | — |